We are dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs

                      Process and Manufacture

                      We have established a comprehensive quality management system in compliance with requirements applicable to and enforced by global competent authorities

                      Explore further

                      Company News

                      Bio-Thera Solutions and Hikma Pharmaceuticals announce exclus

                      Guangzhou and London, 27 August 2021 – Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agree...

                      Bio-Thera Solutions Initiates Phase III Clinical Trial for BA

                      Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for BAT2506, a ...

                      Biogen and Bio-Thera Announce Positive Results From Phase 3 S

                      The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate-to-severe rheumatoid arthritis . CAMBRIDGE, Mass. and GUANGZHOU, C...